Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Rita Teresa Lawlor

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3160-0634; OpenAlex author ID A5045331477. Sources: OpenAlex.

Their work

Papers
80 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
276
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 6 papers · 2018: 3 papers · 2019: 9 papers · 2020: 5 papers · 2021: 14 papers · 2022: 7 papers · 2023: 11 papers · 2024: 10 papers · 2025: 6 papers · 2026: 4 papers

Papers 50 of 80

  1. High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation … Co-author DOI 10.1016/j.humpath.2025.106014↗
  2. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-69013-y↗
  3. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Co-author DOI 10.1038/s41467-026-69762-w↗
  4. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  5. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  6. Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Co-author DOI 10.1002/ijc.35397↗
  7. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  8. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adeno… Co-author DOI 10.1002/ueg2.12676↗
  9. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  10. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  11. Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. Co-author DOI 10.1002/1878-0261.13658↗
  12. A Self-Assembled 3D Model Demonstrates How Stiffness Educates Tumor Cell Phenotypes and Therapy Resistance in Pancreatic Cancer. Co-author DOI 10.1002/adhm.202301941↗
  13. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  14. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.immuni.2024.04.021↗
  15. The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41417-024-00814-3↗
  16. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
  17. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  18. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Co-author DOI 10.1136/gutjnl-2023-329807↗
  19. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. Co-author DOI 10.1186/s13148-024-01623-z↗
  20. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  21. Dissecting the role of toll-like receptor 7 in pancreatic cancer. Co-author DOI 10.1002/cam4.5606↗
  22. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  23. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  24. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  25. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  26. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Co-author DOI 10.1038/s41416-022-02028-6↗
  27. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  28. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  29. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  30. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  31. Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity … Co-author DOI 10.3390/cancers15245753↗
  32. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  33. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00703-8↗
  34. ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. First author DOI 10.1016/s1470-2045(22)00448-x↗
  35. Loss of FGFR4 promotes the malignant phenotype of PDAC. Co-author DOI 10.1038/s41388-022-02432-5↗
  36. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  37. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Co-author DOI 10.1080/14728222.2022.2021397↗
  38. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  39. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  40. Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Co-author DOI 10.1038/s41467-021-25921-9↗
  41. Gα15 in early onset of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-021-94150-3↗
  42. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-021-00192-1↗
  43. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Co-author DOI 10.1073/pnas.2020395118↗
  44. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  45. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  46. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Co-author DOI 10.1136/gutjnl-2020-320726↗
  47. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  48. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  49. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Co-author DOI 10.1186/s13046-021-02153-9↗
  50. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗

Closest collaborators

The 25 strongest of 276 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aldo Scarpa Scarpa · 47 shared papers, 2012–2026 · strength 5.64
  2. Claudio Luchini · 19 shared papers, 2018–2026 · strength 2.57
  3. Roberto Salvia · 16 shared papers, 2017–2026 · strength 2.03
  4. Vincenzo Corbo · 14 shared papers, 2014–2025 · strength 1.67
  5. Giuseppe Malleo · 11 shared papers, 2017–2026 · strength 1.37
  6. Antonio Pea · 10 shared papers, 2018–2026 · strength 1.24
  7. Michèle Milella · 10 shared papers, 2016–2025 · strength 1.19
  8. Andrea Mafficini · 9 shared papers, 2017–2025 · strength 1.16
  9. Thomas Mathias Gress · 9 shared papers, 2017–2025 · strength 0.99
  10. Paola Mattiolo · 6 shared papers, 2020–2026 · strength 0.90
  11. Núria Malats Riera · 8 shared papers, 2017–2025 · strength 0.83
  12. Alfredo Carrato Mena · 8 shared papers, 2017–2025 · strength 0.83
  13. Diana Behrens · 5 shared papers, 2021–2026 · strength 0.79
  14. Tatjana Crnogorac‐Jurcevic · 9 shared papers, 2017–2025 · strength 0.79
  15. Sabrina L. D’Agosto · 6 shared papers, 2019–2025 · strength 0.76
  16. William Greenhalf · 9 shared papers, 2017–2025 · strength 0.72
  17. Lisa Veghini · 5 shared papers, 2022–2025 · strength 0.71
  18. Peter J. Bailey · 6 shared papers, 2014–2025 · strength 0.68
  19. Francesca Lupo · 5 shared papers, 2019–2025 · strength 0.66
  20. Elena Fiorini · 5 shared papers, 2019–2025 · strength 0.66
  21. Lodewijk A.A. Brosens · 5 shared papers, 2021–2025 · strength 0.66
  22. Carmine Carbone · 4 shared papers, 2023–2025 · strength 0.63
  23. Francesco De Sanctis · 5 shared papers, 2019–2024 · strength 0.62
  24. Luis Muñoz‐Bellvís · 7 shared papers, 2017–2025 · strength 0.62
  25. J. Enrique Domínguez‐Muñoz · 7 shared papers, 2017–2025 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.